The Golden Age of Medical Innovation: Critics Grouse about a Sluggish Drug Pipeline, but They Are Looking in the Wrong Place. John Calfee Shows That Innovation in Drugs and Medical Devices in the U.S. Is Rampant. New Treatments Are Fighting Breast Cancer, Macular Degeneration, Rheumatoid Arthritis, and Many More Diseases. Why the Success? (Health Innovation Outlook 2007)

By Calfee, John | The American (Washington, DC), March-April 2007 | Go to article overview
Save to active project

The Golden Age of Medical Innovation: Critics Grouse about a Sluggish Drug Pipeline, but They Are Looking in the Wrong Place. John Calfee Shows That Innovation in Drugs and Medical Devices in the U.S. Is Rampant. New Treatments Are Fighting Breast Cancer, Macular Degeneration, Rheumatoid Arthritis, and Many More Diseases. Why the Success? (Health Innovation Outlook 2007)


Calfee, John, The American (Washington, DC)


LAST DECEMBER, THE editors of Science magazine--the widely respected journal of the American Association for the Advancement of Science--selected ten "breakthroughs" of the year.

Number one was the solution to the "Poincare Conjecture," a topological puzzle that had confounded mathematicians for a century. Number four was the discovery of a 375-million-year-old fossil that filled an evolutionary gap between fish and birds. But it was breakthrough number six that got my attention--"a ray of hope for macular degeneration patients." It related the stunning clinical-trial results for ranibizumab, a drug sold under the brand name Lucentis by Genentech, its developer and manufacturer.

Lucentis is a monoclonal antibody--made, using biotech methods, from genetically engineered bacteria--that attacks a protein responsible for the leading cause of blindness in seniors. Age-related macular degeneration, or AMD, affects a part of the retina and causes blind spots, which expand over time, in the center of the field of vision. It is a disease that had previously defied all attempts even at delaying the inevitable decline toward blindness. But with Lucentis, the eyesight of about 95 percent of AMD patients either improved or stopped getting worse--a stunning achievement.

Biotechnology has lately provided many other breakthroughs. In January, an article in The Lancet, a British medical journal, described the latest striking results for another Genentech drug, Herceptin, which treats an aggressive form of breast cancer that affects about 50,000 women a year. The cancer is characterized by an overabundance of a protein called human epithelial growth factor receptor-2 (HER2), which stimulates the growth of tumors. In 2005, research published in The New England Journal of Medicine found that, when administered after surgery, Herceptin reduced the odds of a recurrence by half. An accompanying editorial concluded that the key result "suggests a dramatic and perhaps permanent perturbation of the natural history of the disease, maybe even a cure," and that "our care of patients with HER2-positive breast cancer must change today." The new Lancet study went even further, documenting mortality declines after only two years of use, an unheard-of result in treating breast cancer. Other biotech treatments approved recently include Enbrel, for psoriasis, a painful skin condition; Remicade, for Crohn's disease, an inflammatory digestive-tract disorder; Rituxan, for rheumatoid arthritis; and Avastin, for several different cancers.

Enbrel was developed by Immunex, a Seattle company that was purchased in 2001 by Amgen, the world's largest biotech firm. Remicade is a product of Centocor, the biomedical firm that pioneered monoclonal antibody technology. And Rituxan and Avastin are from Genentech, one of the early biotech firms that is now seeing a boom in revenues, up 40 percent in 2006 to $9 billion.

The remarkable treatments these firms have developed seem at odds with the widespread notion that medical innovation has all but come to a halt. A recent report by the Government Accountability Office, for example, has warned, in the words of a popular website that covers drug research news, "that the pharmaceutical industry is not producing enough new drugs despite spending more on research and development." In a similar vein, Democratic Representative Henry Waxman, the new chairman of the House Committee on Government Reform, stated, "Many aspects of the drug development system need to be examined to determine how to encourage research that focuses on breakthrough treatments rather than drug industry profits."

Yet breakthroughs are precisely what are being achieved. Why aren't they more widely recognized? One reason is that none of the treatments I have just described would appear on a list of innovative new drug approvals over the past few years. The results all came from clinical trials involving drugs that had already been approved for something else--often a different stage of cancer, sometimes a different type of cancer, and occasionally a different illness altogether.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
Loading One moment ...
Project items
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited article

The Golden Age of Medical Innovation: Critics Grouse about a Sluggish Drug Pipeline, but They Are Looking in the Wrong Place. John Calfee Shows That Innovation in Drugs and Medical Devices in the U.S. Is Rampant. New Treatments Are Fighting Breast Cancer, Macular Degeneration, Rheumatoid Arthritis, and Many More Diseases. Why the Success? (Health Innovation Outlook 2007)
Settings

Settings

Typeface
Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

While we understand printed pages are helpful to our users, this limitation is necessary to help protect our publishers' copyrighted material and prevent its unlawful distribution. We are sorry for any inconvenience.
Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.

Are you sure you want to delete this highlight?